Clinical and epidemiological characteristics of systemic lupus erythematosus in the Republic of Sakha (Yakutia)
https://doi.org/10.25789/YMJ.2024.86.06
Abstract
A retrospective epidemiological study based on the data of the republican register of systemic lupus erythematosus of the Department of Cardio-Rheumatology of the Pediatric Center RH No.1 – M.E. Nikolaev National Centre of Medicine is presented in the article. The peculiarities of the clinical course and therapy of the disease were analyzed taking into account the ethnicity of the patients. It was found out that the incidence of SLE is higher among the residents of the Republic of Sakha (Yakutia) compared to the neighboring regions of the Russian Federation.
About the Authors
S. G. Boeskorova
State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital No.1 M.E. Nikolaev National Centre of Medicine
Russian Federation
Russian Federation
Boeskorova Sargylana Gavrilievna – rheumatologist.
Yakutia
M. V. Afonskaya
State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital No.1 M.E. Nikolaev National Centre of Medicine, chief external rheumatologist of the Republic of Sakha
Russian Federation
Russian Federation
Afonskaya Marina Viktorovna – rheumatologist
Yakutia
V. M. Argunova
State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital No.1 M.E. Nikolaev National Centre of Medicine
Russian Federation
Russian Federation
Argunova Vera Maichna – rheumatologist of the State Autonomous Institution of the Republic of Sakha (Yakutia) Republican Hospital No.1 M.E. Nikolaev National Centre of Medicine, chief external rheumatologist of the FEFD
T. E. Burtseva
Medical Institute of M.K. Ammosov North-Eastern Federal University; Yakut Science Centre of Complex Medical Problems
Russian Federation
Russian Federation
Burtseva Tatyana Egorovna – Doctor of Medical Sciences, Associate Professor, Professor of the Department of Pediatrics and Pediatric Surgery, Medical Institute of M.K. Ammosov North-Eastern Federal University, head of the Laboratory of the Yakut Science Centre of Complex Medical Problems
R. K. Raupov
Federal State Budgetary Institution G.I. Tourner National Medical Research Center of Pediatric Traumatology and Orthopedics
Russian Federation
Russian Federation
Raupov Rinat Kausarovich – Doctor of Medical Sciences, rheumatologist.
St. Petersburg
E. M. Kalashnikova
Pediatric Department No. 3 of the Clinic of St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Kalashnikova Elvira Maratovna – rheumatologist
V. G. Chasnyk
Department of Hospital Pediatrics St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Chasnyk Vyacheslav Grigorievich – Doctor of Medical Sciences, Professor Head
M. M. Kostik
Department of Hospital Pediatrics St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Kostik Mikhail Mikhailovich – Doctor of Medical Sciences, Professor, Professor
References
1. Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia//Almanac of clinical medicine. 2018. V. 46. No. 1. P. 32-39.
2. Ishuova P.K., Maitbasova R.S. Amangeldieva M.P. Systemic lupus erythematosus in children// Issues of organization and informatization of healthcare. 2016. №. 5. P. 138-141.
3. Kuchinskaya E.M., Chasnyk V.G., Kostik M.M. Systemic lupus erythematosus in children: the use of formalized methods for describing the course and outcome of the disease in a retrospective study// Pediatrician. 2017. V. 8. No. 5. P. 35-43. doi: 10.17816/PED8535-43
4. The experience of using rituximab in children with systemic lupus erythematosus: a retrospective study of a series of cases/ M.M. Kostik [et al.] //Issues of modern pediatrics. 2016. V. 15. №. 3. P. 295-300.
5. The use of biological therapy in patients with systemic lupus erythematosus/ E.M. Kalashnikova [et al.]//Treatment and prevention. 2023. V. 13. No. 2. P. 12-17.
6. Systemic lupus erythematosus: clinical recommendations. Part 2. E.I. Alekseeva [et al.]// Issues of modern pediatrics. 2018. 17 (2). P.110–125. doi: 10.15690/vsp.v17i2.1877)
7. Modern clinical and epidemiological characteristics of systemic lupus erythematosus according to the territorial register / D.V. Shaduro [et al.]// Clinical medicine. 2017. V. 95. No. 2. P. 140-147.
8. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus/ A. Fanouriakis [et al.] //Annals of the Rheumatic Diseases 2019; 78 (6): 736-745. DOI: 10.1136/annrheumdis-2019-215089.
9. Basu B. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis//Pediatric nephrology 2017; 32(6): 1013-1021. DOI: 10.1007/s00467-017-3583-x.
10. BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus/ R. Furie [et all]//Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. PMID: 22127708; PMCID: PMC5007058.
11. Cardiovascular events in systemic lupus erythematosus. A nation -wide study in Spain from the RELESSER Registry/ A Fernández-Nebro [et all]//Medicine (Baltimore). 2015;94(29):e1183. doi: 10.1097/MD.0000000000001183.
12. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis/ L.Kang [et al.] //Frontiers in Immunology 2022; 13: 859380. DOI: 10.3389/fimmu.2022.859380
13. Efficacy and Safety of Biologic Agents for Lupus Nephritis А Systematic Review and Meta-analysis/ Chen MS Pang [et al.] //Journal of Clinical Rheumatology. 2023; 29: 95-100. DOI: 10.1097/RHU.0000000000001877
14. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study/ B.H. Rovin [et all] //Arthritis & Rheumatology 2012; 64:1215–1226. DOI: 10.1002/art.34359.
15. Fortuna G., Brennan M.T. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management//Dent Clin North Am 2013;57:631–55. doi:10.1016/j.cden.2013.06.003
16. Kamphuis S., Silverman E.D. Prevalence and burden of pediatric-onset systemic lupus erythematosus//Nat Rev Rheumatol 2010;6:538–46. doi:10.1038/nrrheum.2010.121.
17. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial/ H.I. Brunner [et all]//Ann Rheum Dis. 2020 Oct;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101. Epub 2020 Jul 22. PMID: 32699034; PMCID: PMC7509523.
18. Pediatric lupus nephritis/SVB Pinheiro [et al.] //J Bras Nefrol. 2019 Apr-Jun;41(2):252-265. doi: 10.1590/2175-8239-JBN-2018-0097. Epub 2018 Nov 14. PMID: 30465590; PMCID: PMC6699445.
19. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study/ L. Arnaud [et all]//Autoimmun Rev 2014;13(11):1082-9.
20. ruiz-Irastorza G., Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs//Rheumatology. 2020; 59 (5): 69-81. DOI: 10.1093/rheumatology/keaa403.
21. Sawhney S., Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort//Lupus 2021; 30(11): 1829-1836. DOI: 10.1177/09612033211034567.
22. Smith EMD., Lythgoe H., Hedrich C.M. Current views on lupus in children//Curr Opin Rheumatol. 2023 Mar 1;35(2):68-81. doi: 10.1097/BOR.0000000000000913. Epub 2022 Oct 25. PMID: 36286724.
23. Systemic lupus erythematosus in Iran: A study of 2280 patients over 33 years/ M. Akbarian [et all]//Int J Rheum Dis . 2010. V.13(4). P.374−379
24. Thakral A., Klein-Gitelman M.S. An update on treatment and management of pediatric systemic lupus erythematosus//Rheumatology and Therapy. 2016; 3 (2): 209-219. DOI: 10.1007/s40744-016-0044-0.
25. The incidence and prevalence of systemic lupus erythematosus in the UK, 19992012/F. Rees [et al.]//Ann Rheum Dis 2016. V.75(1).P.136-41.
26. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE/ L. Watson [et al.]//Lupus. 2015 Jan;24(1):10-7. doi: 10.1177/0961203314547793. Epub 2014 Aug 12. PMID: 25117653.
27. Update οn the diagnosis and management of systemic lupus erythematosus/ A. Fanouriakis [et all]//Ann Rheum Dis. 2021 Jan;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272. Epub 2020 Oct 13. PMID: 33051219.
28. Yu H., Nagafuchi Y., Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus//Biomolecules. 2021 Jun 22;11(7):928. doi: 10.3390/biom11070928. PMID: 34206696; PMCID: PMC8301935.
Review
For citations:
Boeskorova S.G., Afonskaya M.V., Argunova V.M., Burtseva T.E., Raupov R.K., Kalashnikova E.M., Chasnyk V.G., Kostik M.M. Clinical and epidemiological characteristics of systemic lupus erythematosus in the Republic of Sakha (Yakutia). Yakut Medical Journal. 2024;(2):26-30. https://doi.org/10.25789/YMJ.2024.86.06
Views:
18
Email this article 